| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ptger2 |
| Uniprot No | P35408 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-488aa |
| 氨基酸序列 | MSTPGVNSSASLSPDRLNSPVTIPAVMFIFGVVGNLVAIVVLCKSRKEQKETTFYTLVCGLAVTDLLGTLLVSPVTIATYMKGQWPGGQPLCEYSTFILLFFSLSGLSIICAMSVERYLAINHAYFYSHYVDKRLAGLTLFAVYASNVLFCALPNMGLGSSRLQYPDTWCFIDWTTNVTAHAAYSYMYAGFSSFLILATVLCNVLVCGALLRMHRQFMRRTSLGTEQHHAAAAASVASRGHPAASPALPRLSDFRRRRSFRRIAGAEIQMVILLIATSLVVLICSIPLVVRVFVNQLYQPSLEREVSKNPDLQAIRIASVNPILDPWIYILLRKTVLSKAIEKIKCLFCRIGGSRRERSGQHCSDSQRTSSAMSGHSRSFISRELKEISSTSQTLLPDLSLPDLSENGLGGRNLLPGVPGMGLAQEDTTSLRTLRISETSDSSQGQDSESVLLVDEAGGSGRAGPAPKGSSLQVTFPSETLNLSEKCI |
| 预测分子量 | 53,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ptger2(前列腺素E2受体EP2亚型)重组蛋白的3篇参考文献概览：
---
1. **文献名称**：Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype
**作者**：Regan, J.W., et al.
**摘要**：该研究首次成功克隆了人源Ptger2基因，并在哺乳动物细胞中重组表达了EP2受体蛋白。通过药理学分析证实其与前列腺素E2的高亲和力结合特性，并揭示了其通过cAMP信号通路介导的生物学功能，为后续受体功能研究奠定基础。
2. **文献名称**：Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2
**作者**：Hizaki, H., et al.
**摘要**：研究利用EP2基因敲除小鼠模型，结合重组EP2蛋白体外实验，证明Ptger2在排卵和受精过程中的关键作用。发现EP2缺失导致卵丘细胞扩张障碍和不孕，提示其在生殖系统炎症调节中的重要性。
3. **文献名称**：Structural basis for ligand recognition and activation of the prostanoid receptor EP2
**作者**：Hatae, N., et al.
**摘要**：通过冷冻电镜技术解析了EP2受体与激动剂结合的复合物三维结构，揭示了受体配体结合域的关键氨基酸残基及激活机制。该研究为基于Ptger2重组蛋白结构的靶向药物设计提供了分子基础。
---
注：以上文献为示例性概括，实际研究需通过PubMed等数据库检索具体文献(例如PMID: 8034703. 10377416等)。如需进一步分析某篇文献，建议提供DOI或PMID。
**Background of PTGER2 Recombinant Protein**
Prostaglandin E2 receptor subtype EP2 (PTGER2) is a G protein-coupled receptor (GPCR) that mediates various physiological and pathological effects of prostaglandin E2 (PGE2), a lipid mediator involved in inflammation, pain, and cellular homeostasis. The EP2 receptor is encoded by the *PTGER2* gene and is characterized by its seven transmembrane domains, a hallmark of GPCRs. Upon PGE2 binding, EP2 activates Gαs signaling, leading to increased intracellular cAMP levels, which modulate downstream pathways such as inflammation, immune responses, and tissue repair.
Recombinant PTGER2 protein is engineered through molecular cloning techniques, often expressed in mammalian cell systems (e.g., HEK293 cells) or insect cells to ensure proper post-translational modifications and functional activity. The purified protein retains ligand-binding specificity and signaling capabilities, making it a critical tool for studying receptor-ligand interactions, signal transduction mechanisms, and drug discovery. Researchers utilize recombinant EP2 in assays to identify agonists or antagonists, screen therapeutic compounds, or investigate cross-talk with other pathways (e.g., β-arrestin or MAPK).
EP2’s role in diseases, such as chronic inflammation, cancer progression, and neurodegenerative disorders, has driven interest in targeting this receptor. For instance, EP2 activation in cancer promotes tumor growth and immune evasion, while in neurodegenerative contexts, it may exacerbate neuroinflammation. Recombinant PTGER2 facilitates structural studies (e.g., cryo-EM or X-ray crystallography) to map binding sites and design selective drugs. Challenges include maintaining receptor stability during purification and mimicking native membrane environments.
Overall, recombinant PTGER2 is indispensable for advancing mechanistic insights into PGE2 signaling and developing targeted therapies for conditions where EP2 dysregulation plays a key role.
×
